Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/25548
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWalsh, JA-
dc.contributor.authorBarker, RE-
dc.contributor.authorKon, SSC-
dc.contributor.authorJones, SE-
dc.contributor.authorBanya, W-
dc.contributor.authorNolan, CM-
dc.contributor.authorPatel, S-
dc.contributor.authorPolgar, O-
dc.contributor.authorHaselden, BM-
dc.contributor.authorPolkey, MI-
dc.contributor.authorCullinan, P-
dc.contributor.authorMan, WDC-
dc.date.accessioned2022-11-26T17:21:27Z-
dc.date.available2022-11-26T17:21:27Z-
dc.date.issued2021-11-11-
dc.identifierORCID iD: Claire Nolan https://orcid.org/0000-0001-9067-599X-
dc.identifier2004047-
dc.identifier.citationWalsh, J.A. et al. (2021) 'Gait speed and adverse outcomes following hospitalised exacerbation of COPD', European Respiratory Journal, 58 (5), 2004047, pp. 1 - 11. doi: 10.1183/13993003.04047-2020.en_US
dc.identifier.issn0903-1936-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/25548-
dc.description.abstractCopyright © 2021 The Authors. Four-metre gait speed (4MGS) is a simple physical performance measure and surrogate marker of frailty that is associated with adverse outcomes in older adults. We aimed to assess the ability of 4MGS to predict prognosis in patients hospitalised with acute exacerbations of COPD (AECOPD).213 participants hospitalised with AECOPD (52% male, mean age and FEV1, 72 years and 35% predicted) were enrolled. 4MGS and baseline demographics were recorded at hospital discharge. All-cause readmission and mortality were collected for 1 y after discharge, and multivariable Cox-proportional hazards regression were performed. Kaplan-Meier and Competing risk analysis was conducted comparing time to all-cause readmission and mortality between 4MGS quartiles.111 participants (52%) were readmitted, and 35 (16%) died during the follow-up period. 4MGS was associated with all-cause readmission, with an adjusted subdistribution hazard ratio of 0.868 (95% CI 0.797-0.945; p=0.001) per 0.1 m·s-1 increase in gait speed, and with all-cause mortality with an adjusted subdistribution hazard ratio of 0.747 (95% CI: 0.622-0.898; p=0.002) per 0.1 m·s-1 increase in gait speed. Readmission and mortality models incorporating 4MGS had higher discrimination than age or FEV1% predicted alone, with areas under the receiver operator characteristic curves of 0.73 and 0.80 respectively. Kaplan-Meier and Competing Risk curves demonstrated that those in slower gait speed quartiles had reduced time to readmission and mortality (log rank both p<0.001).4MGS provides a simple means of identifying at-risk patients with COPD at hospital discharge. This provides valuable information to plan post-discharge care and support.en_US
dc.description.sponsorshipMedical Research Council new investigator research grant awarded to W.D-C. Manen_US
dc.format.extent1 - 11-
dc.format.mediumPrint-Electronic-
dc.languageEnglish-
dc.language.isoenen_US
dc.publisherEuropean Respiratory Societyen_US
dc.rightsCopyright © 2021 the authors. For reproduction rights and permissions contact permissions@ersnet.org This is an author-submitted, peerreviewed version of a manuscript that has been accepted for publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication-
dc.rights.urihttps://erj.ersjournals.com/authors/instructions-
dc.subjectrespiratory system-
dc.titleGait speed and adverse outcomes following hospitalised exacerbation of COPDen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1183/13993003.04047-2020-
dc.relation.isPartOfEuropean Respiratory Journal-
pubs.issue5-
pubs.publication-statusPublished-
pubs.volume58-
dc.identifier.eissn1399-3003-
dc.rights.holderThe authors-
Appears in Collections:Dept of Health Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2021 the authors. For reproduction rights and permissions contact permissions@ersnet.org This is an author-submitted, peerreviewed version of a manuscript that has been accepted for publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication544.4 kBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.